Hepatocellular Carcinoma Identification Using Delta-HLD
ConditionHepato Cellular Carcinoma (HCC)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorEpiliquid Holding, Inc
About this trial
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Eligibility criteria
Qualifiers
Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
Willing and able to provide informed consent
Available paired plasma and liver tissue sample
Disqualifiers
Other active cancers
Prior liver transplantation
Known hereditary cancer syndromes
Recent chemotherapy or antiviral treatment (<3 months)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov